A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

NCT01448707 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV) Infections
Acquired Immunodeficiency Syndrome (AIDS) Virus

Interventions

DRUG: Darunavir
DRUG: Ritonavir

Sponsor

Janssen-Cilag International NV